[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Higher Late Afternoon",
    "summary": "Health care stocks advanced late Tuesday afternoon with the NYSE Health Care Index rising 0.6% and t",
    "url": "https://finnhub.io/api/news?id=23685bd96b89adb153c5aa675dced391bee6879e6e7308dd5a05632fcab97012",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756237863,
      "headline": "Sector Update: Health Care Stocks Higher Late Afternoon",
      "id": 136536784,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Health care stocks advanced late Tuesday afternoon with the NYSE Health Care Index rising 0.6% and t",
      "url": "https://finnhub.io/api/news?id=23685bd96b89adb153c5aa675dced391bee6879e6e7308dd5a05632fcab97012"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=eb39b61b4314cecad29fda985da240cf3d6d78c4dc3a4c669bf720c641086c5a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756225800,
      "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 136547205,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=eb39b61b4314cecad29fda985da240cf3d6d78c4dc3a4c669bf720c641086c5a"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Stocks sink after Trump threatens Fed, overseas tech regulation",
    "summary": "Stocks are sinking in futures after a series of Trump Truth Social posts",
    "url": "https://finnhub.io/api/news?id=be4a9312348a90c3ea8860501ce30cfb685263607a12a92c94bfd956c710613b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756219840,
      "headline": "Stock Market Today: Stocks sink after Trump threatens Fed, overseas tech regulation",
      "id": 136530075,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Stocks are sinking in futures after a series of Trump Truth Social posts",
      "url": "https://finnhub.io/api/news?id=be4a9312348a90c3ea8860501ce30cfb685263607a12a92c94bfd956c710613b"
    }
  },
  {
    "ts": null,
    "headline": "The FDA Extends the Review Deadlines for Two Submissions by Regeneron Pharmaceuticals (REGN)",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued US Stocks According to Wall Street Analysts. On August 20, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that the FDA has extended the review deadlines for two regulatory submissions of EYLEA HD Injection 8 mg to the fourth quarter of 2025. The submissions made to the FDA […]",
    "url": "https://finnhub.io/api/news?id=20eeea9bffc9674e4fe819033312cf89bc958322a10ce530511159133bceb21f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756211972,
      "headline": "The FDA Extends the Review Deadlines for Two Submissions by Regeneron Pharmaceuticals (REGN)",
      "id": 136525947,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued US Stocks According to Wall Street Analysts. On August 20, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that the FDA has extended the review deadlines for two regulatory submissions of EYLEA HD Injection 8 mg to the fourth quarter of 2025. The submissions made to the FDA […]",
      "url": "https://finnhub.io/api/news?id=20eeea9bffc9674e4fe819033312cf89bc958322a10ce530511159133bceb21f"
    }
  },
  {
    "ts": null,
    "headline": "J&J earmarks $2B for Fujifilm’s North Carolina facility",
    "summary": "The 10-year deal will expand the biopharma giant’s capacity to better meet U.S. demand for advanced medicines and create 120 jobs for the Raleigh area.",
    "url": "https://finnhub.io/api/news?id=05b5abc2be75b243b5612af3a06f9a3b2a84e6172eb4c56cd993b8643484b686",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756209240,
      "headline": "J&J earmarks $2B for Fujifilm’s North Carolina facility",
      "id": 136530085,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The 10-year deal will expand the biopharma giant’s capacity to better meet U.S. demand for advanced medicines and create 120 jobs for the Raleigh area.",
      "url": "https://finnhub.io/api/news?id=05b5abc2be75b243b5612af3a06f9a3b2a84e6172eb4c56cd993b8643484b686"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis",
    "summary": "Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score U.S. regulatory submission for cemdisiran monotherapy is planned for the first quarter of 2026, pending discussions with the FDA TARRYTOWN, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the primary and key seco",
    "url": "https://finnhub.io/api/news?id=9f03a022ab83e6588467f902496fd9430e5667e8a085c943d3f0fbac8044c481",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756206000,
      "headline": "Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis",
      "id": 136524117,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score U.S. regulatory submission for cemdisiran monotherapy is planned for the first quarter of 2026, pending discussions with the FDA TARRYTOWN, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the primary and key seco",
      "url": "https://finnhub.io/api/news?id=9f03a022ab83e6588467f902496fd9430e5667e8a085c943d3f0fbac8044c481"
    }
  },
  {
    "ts": null,
    "headline": "Can Regeneron’s Value Shine Through After Recent Stock Slump in 2025?",
    "summary": "If you’re wondering what to do with Regeneron Pharmaceuticals stock right now, you’re not alone. It’s easy to feel torn when a company has a track record of innovation and a share price that’s been on a roller coaster. Over the past year, Regeneron investors have seen some ups and a lot of downs, with the share price dropping more than 52.1% in the last twelve months and ending last week down 0.3%. While there was a brief 1.6% boost over the past month, it hasn’t been enough to reverse a...",
    "url": "https://finnhub.io/api/news?id=5016f7431f9ad0b0132f9eafbdb2bc8bdc51d9b85140eac9867064b07911b02a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756202994,
      "headline": "Can Regeneron’s Value Shine Through After Recent Stock Slump in 2025?",
      "id": 136524118,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "If you’re wondering what to do with Regeneron Pharmaceuticals stock right now, you’re not alone. It’s easy to feel torn when a company has a track record of innovation and a share price that’s been on a roller coaster. Over the past year, Regeneron investors have seen some ups and a lot of downs, with the share price dropping more than 52.1% in the last twelve months and ending last week down 0.3%. While there was a brief 1.6% boost over the past month, it hasn’t been enough to reverse a...",
      "url": "https://finnhub.io/api/news?id=5016f7431f9ad0b0132f9eafbdb2bc8bdc51d9b85140eac9867064b07911b02a"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron: Cemdisiran Hits Goals in Generalized Myasthenia Gravis",
    "summary": "Regeneron: Cemdisiran Hits Goals in Generalized Myasthenia Gravis",
    "url": "https://finnhub.io/api/news?id=a55db1b6a49056c6426591e6fad5d1789d254e9f4f2b65a654f325526d576c65",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756193880,
      "headline": "Regeneron: Cemdisiran Hits Goals in Generalized Myasthenia Gravis",
      "id": 136547206,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron: Cemdisiran Hits Goals in Generalized Myasthenia Gravis",
      "url": "https://finnhub.io/api/news?id=a55db1b6a49056c6426591e6fad5d1789d254e9f4f2b65a654f325526d576c65"
    }
  }
]